
FDA Issues Guidance on Complex Innovative Trial Designs
The new guidance provides information on how sponsors should interact with the agency regarding complex innovative trial design proposals.
FDA published
The guidance discusses meeting availability, recommended common elements of CID proposals, recommended elements of Bayesian CID proposals, and simulations. It also provides examples of CID and information recommended to facilitate interactions.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.